Skip to main content

Table 6 Concurrent change: time integrated concentration of biochemical markers C1M, C2M, C3M, CRPM, and hsPRO-C2 and changes in BML over 24 months

From: Association of biochemical markers with bone marrow lesion changes on imaging—data from the Foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium

BMLs

Serum C1M

Serum C2M

Serum C3M

Serum CRPM

Serum hsPRO-C2

Maximum size

0.98

0.92

1.08

0.96

0.97

P = 0.858

P = 0.411

P = 0.345

P = 0.528

P = 0.799

(0.82, 1.17)

(0.76, 1.12)

(0.92, 1.27)

(0.83, 1.10)

(0.79, 1.19)

Number of subregions

1.05

1.16

1.05

1.96

1.13

0.591

P = 0.138

P = 0.570

P = 0.613

P = 0.285

(0.88, 1.25)

(0.95, 1.41)

(0.89, 1.22)

(0.84, 1.11)

(0.90, 1.43)

  1. BMLs bone marrow lesions, OR odds ratio, 95% CI 95% confidence interval, C1M, C2M, C3M serum type I, type II and type III collagen degradation mediated by matrix metalloproteinase (MMP) cleavage, hsPRO-C2 serum propeptide of type IIb collagen, CRPM serum metabolite of C-reactive protein
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us